Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan

TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based drug design (SBDD) and development, is pleased to announce it has won Licensing Deal of the Year and Executive of the Year at the first Informa Pharma Intelligence Awards Japan held yesterday in Tokyo.

The Informa Pharma Intelligence Awards Japan, the Japanese rendition of the prestigious global Scrip Awards which have been running for 17 years, recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market. The categories were judged by a panel of industry experts within academia and business, from around Japan.

Licensing Deal of the Year recognizes deals that were closed during 2021, and the judges looked at all aspects from monetary and strategic value to the benefits they give to both sides.

Sosei Heptares’ winning deal was for its potentially multi-billion dollar strategic collaboration and licensing agreement with Neurocrine Biosciences to develop novel muscarinic receptor agonists for the treatment of schizophrenia and other neuropsychiatric disorders, signed in November 2021. Muscarinic receptors are GPCRs found in multiple tissues including the brain, cardiovascular system and gastrointestinal tract. Selective activation of M4 and M1 receptors in the brain is a clinically validated approach to treating cognitive and neuropsychological symptoms for a variety of neurological diseases.

Under the deal, Neurocrine gains development and commercialization rights to a broad portfolio of novel, clinical and preclinical muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares. Neurocrine plans to initiate a Phase 2 trial this year with NBI-1117568 (formerly HTL-0016878), an oral, selective muscarinic M4 receptor agonist, as a potential new treatment for schizophrenia.

Sosei Heptares is eligible to receive R&D funding plus development, regulatory and commercial milestones of up to US$2.6 billion, as well as retaining the rights to develop M1 agonists in Japan in all indications.

Executive of the Year, awarded to Chris Cargill, President and CEO of Sosei Heptares (CFO at the time of nomination), acknowledges his excellence in leadership throughout 2021, where his efforts have been instrumental in enabling the Company to progress and achieve significant development and partnering milestones. Furthermore, Mr. Cargill has been a strong force in driving Sosei Heptares’ growth strategies and evolution, which also saw him promoted to President and CEO in 2022.

Chris Cargill, President and CEO of Sosei Heptares, commented: “We are honored to receive such prestigious awards at this first-ever Japan-focused event. I would like to thank everyone at Sosei Heptares for their continued dedication and tireless efforts as we strive to accelerate the development of new medicines for patients through application of our world-leading drug discovery and translational medicine capabilities, while at the same time making further contributions to patients in Japan.”

About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR^® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR^® are trademarks of Sosei Group companies.

For more information, please visit https://soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Enquiries:

Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, Chief Financial Officer
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Candelle Chong, SVP Investor Relations and Corporate Strategy
Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 | [email protected]

MEDiSTRAVA Consulting (for International Media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0)203 928 6900| [email protected]

Sosei Heptares Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.